By Marie Rosenthal
The FDA approved ibrexafungerp tablets (Brexafemme, SCYNEXIS) as a one-day oral treatment for vulvovaginal candidiasis (VVC). The drug is from the triterpenoid class, making it the first oral option in more than 40 years that does not belong to the azoles class.
The company is also investigating the use of ibrexafungerp as a salvage treatment for patients with a variety of difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to, intolerant of